Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07010159Phase 2Recruiting

Phase 2/3 Study of KPL-387 in Recurrent Pericarditis

Role: lead

NCT07288216Phase 2Recruiting

Transition to KPL-387 Monotherapy Dosing & Administration Study

Role: lead

NCT04687358Active Not Recruiting

REgiStry Of the NAtural History of recurreNt periCarditis in pEdiatric and Adult Patients

Role: lead

NCT06531395Phase 2Terminated

A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease

Role: lead

NCT04447469Phase 2Completed

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

Role: lead

All 5 trials loaded